Substance P enhances mesenchymal stem cells-mediated immune modulation

Cytokine

Volumn 71, Issue 2, 2015, Pages 145-153

  Jin, Yinji ^a   Hong, Hyun Sook ^b   Son, Youngsook ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Immune modulation; Mesenchymal stem cells; Substance P; T cells; TGF 1

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; CD3 ANTIBODY; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY CD28; SB 505124; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CULTURE MEDIUM; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; SENESCENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; COCULTURE; CULTURE MEDIUM; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PHARMACOLOGY; SECRETION (PROCESS); TIME;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; JURKAT CELLS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; SUBSTANCE P; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84910685231     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.003     Document Type: Article

References (39)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. El-denshary E.S.M., Rashed L.A., Elhussiny M. Immunosuppressive effects of mesenchymal stem cells versus corticosteroid in experimental model of arthritis. Clin Exp Pharmacol 2012, S5:003.
3. Semedo P., Correa-Costa M., Antonio Cenedeze M., Maria Avancini Costa Malheiros D., Antonia dos Reis M., et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cell 2009, 27:3063-3073.
4. Li Diangeng, Wang Nan, Zhang Li, Hanyu Zhu, et al. Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor. Stem Cell Res Ther 2013, 4:103-113.
5. Centeno C.J., Schultz J.R., Cheever M., Robinson B., Freeman M., Marasco W. Safety and complications reporting on the re-implantation of culture expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2010, 5:81-93.
6. Bartholomew A., Patil S., Mackay A., Nelson M., Buyaner D., Hardy W., et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001, 12:1527-1541.
7. Casiraghi F., Azzollini N., Cassis P., Imberti B., Morigi M., Cugini D., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181:3933-3946.
8. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., et al. Rapid hematopoietic recovery after coinfusion of autologousblood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
9. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
10. Wang L., Wang L., Cong X., Liu G., Zhou J., et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cell Dev 2013, 22:3192-3202.
11. Huang S.P., Huang C.H., Shyu J.F., et al. Promotion of wound healing using adipose-derived stem cells in radiation ulcer of a rat model. J Biomed Sci 2013, 20:51-60.
12. Hayato Kurata, Rie Tamai, Takeshi Katsuda, Shumpei Ishikawa, et al. Adipose tissue-derived mesenchymal stem cells in regenerative medicine treatment for liver cirrhosis - focused on efficacy and safety in preclinical and clinical studies. JSM Regen Med 2014, 2:1012-1019.
13. Hong H.S., UM J.H., Lee Z.H., Son Y.S. Long-term comparative study of Substance-P with methylprednisolone on the development of osteoporosis. J Toxicol Sci 2014, 39:391-399.
14. Crisostomo P.R., Wang M., Wairiuko G.M., Morrell E.D., Terrell A.M., Seshadri P., et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006, 26:575-580.
15. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
16. Németh K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E (2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
17. Ghannam S., Bouffi C., Djouad F., Jorgensen C., Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010, 1:2-8.
18. Liu H., Lu K., MacAry P.A., Wong K.L., Heng A., Cao T., et al. Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells. J Cell Sci 2012, 125:200-208.
19. Carr C.A., Stuckey D.J., Tatton L., Tyler D.J., Hale S.J., Sweeney D., et al. Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 2008, 295:H533-H542.
20. Hong H.S., Lee J., Lee E., Kwon Y.S., Lee E., Ahn W., et al. A new role of Substance P as an injury-inducible messenger for mobilization of CD29+ stromal-like cells. Nat Med 2009, 15:425-435.
21. Hiramoto M., Aizawa S., Iwase O., Nakano M., Toyama K., Hoque M., et al. Stimulatory effects of Substance P on CD34 positive cell proliferation and differentiation in vitro are mediated by the modulation of stromal cell function. Int J Mol Med 1998, 1:347-354.
22. Harrison S., Geppetti P. Substance P. Int J Biochem Cell Biol 2001, 33:555-576.
23. Ko I.K., Ju Y.M., Chen T., Atala A., Yoo J.J., Lee S.J. Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration. FASEB J 2012, 26:158-168.
24. Hu D., Chen B., Zhu X., Tao K., Tang C., Substance Wang J., et al. Up-regulates the TGF-beta 1 mRNA expression of human dermal fibroblasts in vitro. Zhonghua Zheng Xing Wai Ke Za Zhi 2002, 18:234-236.
25. Gandhi R., Kumar D., Burns E.J., Nadeau M., Dake B., Laroni A., et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010, 11:846-853.
26. Gilbert K., Thoman M., Bauche K., Pham T., Weigle W. Transforming growth factor- beta 1 induces antigen-specific unresponsiveness in naive T cells. Immunol Invest 1997, 26:459-472.
27. Wahl S.M., Wen J., Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006, 213:213-227.
28. Liu H., Kemeny D.M., Heng B.C., Ouyang H.W., Melendez A.J., Cao T. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 2006, 176:2864-2871.
29. Jiang M.H., Lim J.E., Chi G.F., Ahn W.S., Zhang M., Chung E., et al. Substance P reduces apoptotic cell death possibly by modulating the immune response at the early stage after spinal cord injury. NeuroReport 2013, 24:846-851.
30. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD252 naive T cells to CD4+CD25+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
31. Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., Neurath M.F. Cutting edge: TGF-b induces a regulatory phenotype in CD4+CD252 T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004, 2004(172):5149-5153.
32. Liu Y., Zhang P., Li J., Kulkarni A.B., Perruche S., Chen W. A critical function for TGF-β signaling in the development of natural CD4+CD25+ Foxp3+ regulatory T cells. Nat Immunol 2008, 9:632-640.
33. Davidson T.S., DiPaolo R.J., Andersson J., Shevach E.M. Cutting edge: IL-2 is essential for TGF-b-mediated induction of Foxp3+ T regulatory cells. J Immunol 2007, 178:4022-4026.
34. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-b to convert naive CD4+CD252 cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-2027.
35. Delisle J.S., Giroux M., Boucher G., Landry J.R., Hardy M.P., Lemieux S., et al. The TGF-b-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells. Genes Immun 2013, 14:115-126.
36. Bright J.J., Kerr L.D., Sriram S. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J Immunol 1997, 159:175-183.
37. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
38. Du Y.Y., Zhou S.H., Zhou T., Su H., Pan H.W., Du W.H., et al. Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction. Cytotherapy 2008, 10:469-478.
39. Kuo Y.R., Chen C.C., Goto S., Lin P.Y., Wei F.C., Chen C.L. Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation. Clin Dev Immunol 2012, 2012:854846.